TrakCel design, deploy and support digital Cellular Orchestration Solutions that track and manage all the components of the Cell and Gene Therapy supply chain, helping therapy developers to deliver therapies to patients safely and efficiently for both clinical and commercial stage therapies.
For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do.
We innovate.
We unite.
We transform tomorrow.
Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo.
Join us. See the journey.
For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do.
We innovate.
We unite.
We transform tomorrow.
Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo.
Join us. See the journey.
Location: United Kingdom
Employees: 51-200
Founded date: 2012
Investors 3
Mentions in press and media 6
| Date | Title | Description |
| 25.01.2022 | AmerisourceBergen and TrakCel Launch Integrated Platform to Support Cell and Gene Therapies | The integration of TrakCel’s OCELLOS and Lash Group’s Fusion aims to improve speed-to-therapy by increasing connectivity between providers and hub patient services Conshohocken, Pa. (January 25, 2022) – AmerisourceBergen, a global healthca... |
| 05.03.2021 | TrakCel Receives Strategic Investment | TrakCel, a Cardiff, Wales-based supplier of cellular orchestration solutions supporting the cell and gene therapy industry, closed its latest funding round of undisclosed amount. The round was led by AmerisourceBergen and Labcorp (NYSE: LH)... |
| 16.04.2018 | Cell-therapy startup raises $33.5M from Canaan, Bill Maris’s Section 32 and others | Section 32 is the San Diego-based venture capital firm that that Bill Maris, the former CEO of Google Ventures founder. Pellini joined in December while continuing to be the chairman of Foundation Medicine. It was a quick sell from his pers... |
| 19.10.2016 | TrakCel Receives an Equity Investment from Telegraph Hill Partners | TrakCel, a Cardiff, Wales, UK-based cellular orchestration platform developer, received a multi-million dollar investment from San Francisco-based Telegraph Hill Partners. The company intends to use the funds for growth activities. Concurre... |
| 15.10.2016 | THP invests in leading Cellular Orchestration Platform developer, TrakCel | CARDIFF, WALES, UK – TrakCel, the leading provider of cellular orchestration technology to aid in the delivery of regenerative therapies, has successfully completed a multi-million dollar investment by San Francisco-based Telegraph Hill Par... |
| - | Cell-therapy startup raises $33.5M from Canaan, Bill Maris’s Section 32 and others | With a platform promising protection against cell-based therapy supply-chain missteps, Vineti has completed a $33.5 million Series B infusion. Along with the funding, led by Canaan Partners and DFJ, Vineti’s getting two new board members: N... |